Mode
Text Size
Log in / Sign up
N/A N=24 Treatment

Adhesive Tape Trauma Evaluation of a New Gentle Tape in Healthy Infant Subjects

Skin (FLACC Scores of Test Subjects) After Tape Removal

Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcome: Primary: The Face, Legs, Activity, Cry, Consolability (FLACC) Score. — 0.29 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Multi-Purpose Gentle Tape (Device)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Solventum US LLC
Primary completion
Jan 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
The Face, Legs, Activity, Cry, Consolability (FLACC) Score.
0.29

Summary

The objective of this study is to determine the relative gentleness of a new medical tape.

Eligibility Criteria

Inclusion Criteria: Subjects will be infants or children of either gender who meet the following criteria:

  • Who are healthy and who have intact skin at the test site with a baseline score of 0 for erythema
  • Who are between the ages of 6 months - 4 years of age (48 months)
  • Who have a Fitzpatrick Skin Type of I, II or III
  • Whose parent or legal representative agrees to not use any products (i.e. topical medications, creams, powders or ointments) on the test sites for 24 hours prior to the study start date
  • Whose parent or legal representative agrees to sponge bathe their child during the study but agrees to not bathe their child 1 hour before each visit.
  • Whose parent or legal representative agrees to not soak the tape during a sponge bath. If the site gets wet, parent or legal representative agrees to pat their child's back dry (no rubbing).
  • Whose parent or legal representative is willing to sign the Informed Consent Form (with photo release) and HIPAA Authorization.

Exclusion Criteria

  • Who are known to be developmentally delayed
  • Who have any known allergy or sensitivity to tapes
  • Who have sunburn, skin infection or scars, moles, or other blemishes on the back that would obscure grading of the test site
  • Who have had any exposure to other topical medications, creams, powders, or ointments on the test sites 24 hours prior to the start of the study
  • Who have had a strep infection within the 2 weeks prior to the start of the study
  • Who have a history of uncontrolled diabetes, psoriasis, any active dermatitis, or recent history of dermatitis or skin reactions
  • Has participated in any study in the last 2 weeks, or are currently participating in another study, or are scheduled to participate in another study during this study period.
  • Has any other skin disorders that, in the opinion of the investigator, will interfere with the study results or will increase undue risk for the child.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03470012). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search